Dasatinib in imatinib-resistant or -intolerant CML patients:
data from the clinical practice of 6 hematological centers in
the Czech Republic

J 2010

Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic

KLAMOVA, H.; E. FABER; Daniela ŽÁČKOVÁ; M. MARKOVA; J. VOGLOVA et al.

Základní údaje

Originální název

Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic

Autoři

Vydání

Neoplasma, Slovakia, Slovak Academic Press, Ltd, 2010, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.449

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/10:00051558

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.4149/neo_2010_04_355

UT WoS

000278262000010

Klíčová slova anglicky

chronic myeloid leukemia; dasatinib; cytogenetic response; mutation

Příznaky

Mezinárodní význam

Změněno: 20. 4. 2012 15:03, Mgr. Michal Petr

Anotace

V originále

Dasatinib is effective second line treatment for patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib. We report here the first experiences with dasatinib therapy in 71 CML patients resistant or intolerant to imatinib from the real clinical practice of 6 hematological centers in the Czech Republic. Dose 100 mg daily and 70 mg twice daily was administered to patients with chronic phase (CP) and advanced phases (AP) CML. In chronic phase (n=46), complete hematological reponse (CHR) was achieved in 97%, major cytogenetic reponse (MCgR) in 77% and complete cytogenetic response (CCgR) in 67%. Major molecular reponse (MMR) was achieved in 19/31 patients in median of 10 months. In advanced phase (n=25), CHR was attained in 77%, MCgR in 39%, CCgR in 33% and MMR in 2/18 patients. Eleven different baseline mutations were followed up in 15 patients. Dasatinib eliminated mutations in most of the patients, but 3 patients acquired a new one. Novel mutations were detected under dasatinib therapy in 2 patients. Dasatinib was well tolerated, cytopenias were common and was managed by dose modification. The estimated progression free survival (PFS) at 12 months was 97+/-3% in CP and 62+/-21% in AP. The median time to treatment failure was 605 days in AP while it was not reached in CP patients. Our clinical experiences, described here, confirmed that dasatinib is associated with high response rates especially in imatinib resistant or intolerant CML patients in chronic phase.

Citovat

KLAMOVA, H.; E. FABER; Daniela ŽÁČKOVÁ; M. MARKOVA; J. VOGLOVA; E. CMUNT; L. NOVAKOVA; K. MACHOVA-POLAKOVA; J. MORAVCOVA; Dana DVOŘÁKOVÁ; K. MICHALOVA; J. BREZINOVA; Alexandra OLTOVÁ; Marie JAROŠOVÁ; Petr CETKOVSKÝ; K. INDRAK a Jiří MAYER. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic. Neoplasma. Slovakia: Slovak Academic Press, Ltd, 2010, roč. 57, č. 4, s. 355-359. ISSN 0028-2685. Dostupné z: https://doi.org/10.4149/neo_2010_04_355.

@article{910409,
   author = {Klamova, H. and Faber, E. and Žáčková, Daniela and Markova, M. and Voglova, J. and Cmunt, E. and Novakova, L. and MachovaandPolakova, K. and Moravcova, J. and Dvořáková, Dana and Michalova, K. and Brezinova, J. and Oltová, Alexandra and Jarošová, Marie and Cetkovský, Petr and Indrak, K. and Mayer, Jiří},
   article_location = {Slovakia},
   article_number = {4},
   doi = {https://doi.org/10.4149/neo_2010_04_355},
   keywords = {chronic myeloid leukemia; dasatinib; cytogenetic response; mutation},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic},
   volume = {57},
   year = {2010}
}

TY  - JOUR
ID  - 910409
AU  - Klamova, H. - Faber, E. - Žáčková, Daniela - Markova, M. - Voglova, J. - Cmunt, E. - Novakova, L. - Machova-Polakova, K. - Moravcova, J. - Dvořáková, Dana - Michalova, K. - Brezinova, J. - Oltová, Alexandra - Jarošová, Marie - Cetkovský, Petr - Indrak, K. - Mayer, Jiří
PY  - 2010
TI  - Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic
JF  - Neoplasma
VL  - 57
IS  - 4
SP  - 355-359
EP  - 355-359
PB  - Slovak Academic Press, Ltd
SN  - 00282685
KW  - chronic myeloid leukemia
KW  - dasatinib
KW  - cytogenetic response
KW  - mutation
N2  - Dasatinib is effective second line treatment for patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib. We report here the first experiences with dasatinib therapy in 71 CML patients resistant or intolerant to imatinib from the real clinical practice of 6 hematological centers in the Czech Republic. Dose 100 mg daily and 70 mg twice daily was administered to patients with chronic phase (CP) and advanced phases (AP) CML. In chronic phase (n=46), complete hematological reponse (CHR) was achieved in 97%, major cytogenetic reponse (MCgR) in 77% and complete cytogenetic response (CCgR) in 67%. Major molecular reponse (MMR) was achieved in 19/31 patients in median of 10 months. In advanced phase (n=25), CHR was attained in 77%, MCgR in 39%, CCgR in 33% and MMR in 2/18 patients. Eleven different baseline mutations were followed up in 15 patients. Dasatinib eliminated mutations in most of the patients, but 3 patients acquired a new one. Novel mutations were detected under dasatinib therapy in 2 patients. Dasatinib was well tolerated, cytopenias were common and was managed by dose modification. The estimated progression free survival (PFS) at 12 months was 97+/-3% in CP and 62+/-21% in AP. The median time to treatment failure was 605 days in AP while it was not reached in CP patients. Our clinical experiences, described here, confirmed that dasatinib is associated with high response rates especially in imatinib resistant or intolerant CML patients in chronic phase.
ER  -

KLAMOVA, H.; E. FABER; Daniela ŽÁČKOVÁ; M. MARKOVA; J. VOGLOVA; E. CMUNT; L. NOVAKOVA; K. MACHOVA-POLAKOVA; J. MORAVCOVA; Dana DVOŘÁKOVÁ; K. MICHALOVA; J. BREZINOVA; Alexandra OLTOVÁ; Marie JAROŠOVÁ; Petr CETKOVSKÝ; K. INDRAK a Jiří MAYER. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic. \textit{Neoplasma}. Slovakia: Slovak Academic Press, Ltd, 2010, roč.~57, č.~4, s.~355-359. ISSN~0028-2685. Dostupné z: https://doi.org/10.4149/neo\_{}2010\_{}04\_{}355.

Přehled o publikaci